Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.3256 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Follow the EMPULSE: In-hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction.
Eur J Heart Fail
April 2024
Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Eur J Heart Fail
October 2022
Institute of Heart Diseases, Medical University, Wroclaw, Poland.
Aim: The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure, SGLT2 inhibitors cause an early decline in estimated glomerular filtration rate (eGFR) followed by a slower eGFR decline over time than placebo. However, the effects of SGLT2 inhibitors on renal function during a hospital admission for acute heart failure remain largely unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!